Distribution Growth DBS has established distribution partnerships with Cardinal Health (2025), ESBE Scientific (2022), and Rockland Immunochemicals (2021), plus a Canada office expansion in 2022, signaling a scalable go-to-market and cross-border reach. These channels create sales opportunities to accelerate adoption of DBS's specialty IHC reagents and services through distributors and regional teams, with potential for co-marketing programs and regional product bundles in North America and beyond.

Regulatory Advantage As an FDA registered medical device manufacturer under 21 CFR Part 820 and ISO 9001:2008 certified, with CE-marked devices for Europe, DBS presents a strong compliance story to regulated pathology labs, contract research organizations, and biopharma partners. This quality footprint supports longer, more secure contracts and scale across hospital networks needing audit-ready IHC reagents and end-to-end services.

IHC Portfolio DBS offers a focused portfolio in specialty IHC reagents including monoclonal and polyclonal antibodies, detection systems, and multiplex staining reagents, plus custom antibody production services. The ability to provide end-to-end IHC solutions and the launch of conjugated fluorescent antibodies positions DBS to upsell multiplex workflows, bespoke panels, and validated antibody-dye combinations to labs expanding pathology assays.

Agile & Global With a lean team of 11-50 employees and global reach, DBS can move quickly to meet customer needs and support partners, leveraging its ecommerce and site infrastructure. This agility is attractive to mid-size labs, CROs, and academic customers seeking flexible supplier relationships, training, on-site support, and customized solutions without the bureaucracy of larger incumbents.

Market Growth The product direction aligns with rising demand for pathology-based diagnostics and multiplexed biomarker panels in clinical research and labs. DBS's track record of product introductions and international expansion suggests growth potential in North America and Europe via distributors and direct channels, offering collaboration opportunities on biomarker panels, assay development, and co-marketing to capture share in the expanding IHC market.